Regenetech
Kyle Shanks, President
17045 El Camino Real
Suite 101
Houston, TX 77058
Office (281) 480-8899
Cell (832) 414-9520
Fax (281) 480-4998

Copyright 2011©
All Rights Reserved

 

Regenetech has evolved into a highly diverse biotechnology opportunity.
Our short-term plan is to launch an innovative cosmetic line of products by March 31, 2011. These products will contain valuable bio-molecules produced in Simulate Microgravity (using exclusive NASA technology). We have achieved outstanding testing results in these products, with further breakthroughs sure to come.

Our shareholders will be rewarded by this revenue in two ways:

1) A nice return on investment through dividend payment based on net profits of cosmetics; and
2) A portion of these net profits will be devoted to the actual therapies involving cardio-vascular treatments, diabetes, orthopedics and other therapies. Our shareholders will have the satisfaction of being on the cutting edge of cosmetics development and Adult Stem Cell therapies. We will lead breakthroughs in both areas.

 
PRIVATE OFFERING
Regenetech, Inc. has authorized the sale of 2 million shares of common stock. This offering is available to Accredited Individuals and to Institutional and Corporate investors. (Interested parties should contact us for details of the offering)

 

Terms of Use The information contained on this Investor Relations web site is provided for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities. The financial and other information that may be accessed on this investor Relations page speaks only as of the particular dates referenced in the information or the dates the information was originally issued. This information may have since become superseded as a result of later circumstances or events. Regenetech� does not undertake any obligation, and disclaims any duty, to update this information. In addition, this information may contain forward-looking statements that are subject to various risks and uncertainties that could cause actual outcomes or results to differ materially from those expressed in or implied by any forward-looking statement.


Please contact us for more information using the following phone numbers or email addresses.
Note: For security reasons, please do not send confidential or personal information through email.

General Inquiries:

Phone 281-480-8899
(24 hours a day / 7 days a week)
Email: InvestorInfo@regenetech.com
Facsimile 281-480-4998

 
{Trac}